Peptides for Weight Loss: What Actually Works in 2026

Medically reviewed by the Rite Aid Health Team · Last updated July 30, 2026

Weight-loss goals can call for different treatments.

Tesamorelin targets visceral fat.
MOTS-c is studied for metabolic function.
GLP-1 medications such as semaglutide and tirzepatide drive most medical weight loss today.

Use this peptide therapy guide to compare mechanism, evidence, and the next step that fits your goal.

Almost done

We sent the first email to .

A quick confirmation helps ensure future updates reach the right inbox.

We also sent a verification text. Reply YES to confirm your phone number.

1

Confirm your email

Open the first email and click the confirmation link.
2

Only after step 1

Then your discount is reserved

Once you confirm, we reserve your discount and will notify you when peptide services launch.

The first email should arrive within a minute. Do not see it? Check spam or promotions.

Get 20% off your first compounded-peptide order

Join the early-access waitlist and we'll notify you the moment consultations and ordering open.

I agree to receive Rite Aid peptide news and offers by email and, if I provide a phone number, by text.

Which option fits your weight-loss goal?

Peptide	What it targets	Evidence	Route
Tesamorelin	Visceral (abdominal) fat	FDA-approved for HIV-associated lipodystrophy; reduces visceral adipose tissue	Prescription
MOTS-c	Metabolic regulation, insulin sensitivity	Mitochondrial-derived peptide; mostly preclinical	Research / not FDA-approved; favorable advisory vote, final FDA decision pending
GLP-1 medications (semaglutide, tirzepatide)	Appetite, satiety, glucose	FDA-approved, large clinical trial base	Prescription — see the readiness quiz

Tesamorelin — the FDA-approved option

Tesamorelin is the peptide in this group with an FDA approval for visceral fat reduction. It's a growth-hormone-releasing hormone analog approved to reduce visceral adipose tissue (the deep abdominal fat around the organs) in a specific population. It raises growth hormone and IGF-1, which shifts body composition toward less visceral fat. It is not a general weight-loss drug and does not drive the appetite suppression GLP-1s do, but for visceral fat specifically it has the strongest evidence.

MOTS-c — the metabolic peptide

MOTS-c is a mitochondrial-derived peptide studied for insulin sensitivity, glucose handling, and metabolic flexibility. Human evidence is early. A July 2026 advisory vote supported its use in compounding, but the FDA has not made a final decision.

Where GLP-1 medications fit

If your goal is appetite-driven weight loss, GLP-1 receptor agonists — semaglutide and tirzepatide — are the established medical path, with the largest clinical trial base in this category. They're peptides, but they work on a different axis: satiety and glucose regulation rather than growth hormone. If you're weighing a GLP-1, take the GLP-1 weight-loss readiness quiz to see where you stand before a consultation.

How they work for weight loss

These peptides don't share one mechanism — which is why "best peptide for weight loss" has no single answer:

Tesamorelin signals the pituitary to release growth hormone, which raises IGF-1 and preferentially mobilizes visceral fat.
MOTS-c acts inside the mitochondria to influence how cells use glucose and fat for energy, improving metabolic efficiency in research models.
GLP-1 medications slow gastric emptying and act on appetite centers in the brain, reducing how much you eat.

Growth-hormone peptides and GLP-1s can complement different goals — body recomposition versus appetite-driven loss — but they should only be combined under a provider's supervision.

Almost done

We sent the first email to .

A quick confirmation helps ensure future updates reach the right inbox.

We also sent a verification text. Reply YES to confirm your phone number.

1

Confirm your email

Open the first email and click the confirmation link.
2

Only after step 1

Then your discount is reserved

Once you confirm, we reserve your discount and will notify you when peptide services launch.

The first email should arrive within a minute. Do not see it? Check spam or promotions.

Get 20% off your first compounded-peptide order

Join the early-access waitlist and we'll notify you the moment consultations and ordering open.

I agree to receive Rite Aid peptide news and offers by email and, if I provide a phone number, by text.

Blood work before a weight-loss cycle

Establish a baseline before starting anything, and re-test during the cycle to see whether it's working:

Comprehensive Metabolic Profile — glucose, liver enzymes, and kidney function (eGFR); the safety baseline for any cycle and a glucose readout for metabolic peptides.
Men's Hormone Health Checkup / Women's Hormone Health Checkup — hormones that drive body composition, including the IGF-1 axis tesamorelin moves.

Baseline tests before a peptide cycle

Check safety and response markers before starting. These tests help establish a baseline for liver, kidney, glucose, hormone, and recovery tracking.

IGF-1 Test Comprehensive Metabolic Profile Men's Hormone Health Checkup Women's Hormone Health Checkup

Almost done

We sent the first email to .

A quick confirmation helps ensure future updates reach the right inbox.

We also sent a verification text. Reply YES to confirm your phone number.

1

Confirm your email

Open the first email and click the confirmation link.
2

Only after step 1

Then your discount is reserved

Once you confirm, we reserve your discount and will notify you when peptide services launch.

The first email should arrive within a minute. Do not see it? Check spam or promotions.

Get 20% off your first compounded-peptide order

Join the early-access waitlist and we'll notify you the moment consultations and ordering open.

I agree to receive Rite Aid peptide news and offers by email and, if I provide a phone number, by text.

For general education only — not medical advice or a treatment recommendation. Peptides are not a substitute for care from a licensed provider. Talk to a qualified healthcare professional before you start, stop, or change any peptide, medication, or supplement.

FAQ

There's no single answer. Tesamorelin has the strongest evidence for visceral (abdominal) fat, but it is FDA-approved only for HIV-associated lipodystrophy — not for general weight loss. MOTS-c targets metabolic function and is still early in human research. For appetite-driven weight loss, GLP-1 medications like semaglutide and tirzepatide have the largest clinical base.

Yes. Semaglutide and tirzepatide are peptide-based GLP-1 receptor agonists. They work on appetite and glucose regulation rather than growth hormone. Take the readiness quiz if you're considering one.

Tesamorelin and GLP-1 medications require a prescription. MOTS-c is not FDA-approved. An advisory committee supported it for the Section 503A Bulks List in July 2026, but the FDA has not made a final decision.

A comprehensive metabolic profile for glucose, liver, and kidney function, plus a hormone panel. Test at baseline and again during the cycle.

It varies by peptide and goal. Tesamorelin's effect on visceral fat is typically assessed over months. GLP-1 medications produce appetite changes within weeks.